ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
Endothelial Dysfunction in Patients With Erectile Dysfunction: A Double-Blind, Randomized-Control Trial Using Tadalafil
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 134857" data-attributes="member: 13851"><p><strong><span style="color: rgb(184, 49, 47)">Objective: </span></strong>To assess whether tadalafil improves endothelial dysfunction(EnD) in a placebo-controlled randomized-control trial. </p><p></p><p></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Methods:</span></strong> Erectile dysfunction and EnD were assessed by the International Index of Erectile Function (IIEF-5) and flow-mediated dilation (FMD) of the brachial artery respectively, at baseline and 4 weeks by blinded observer. Patients with FMD of < 15% were randomized in 1:1 ratio to receive either placebo or tadalafil. Both placebo and tadalafil in similar-appearing capsules but coded separately, were dispensed by a blinded co-investigator. Compliance and drug-related events were recorded. The randomization codes were then decoded and appropriate statistical tests applied. </p><p></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Results: </span></strong>89 patients were randomized and 82 completed the study. Both groups were comparable. Posttreatment, there were significant improvements in IIEF-5 score (pre- vs post treatment; tadalafil: 11.432 vs 15.937, P < .001 and placebo 11.232 vs 14.935, P < .00) and FMD% pre- vs post treatment; tadalafil: 11.222 vs 13.827, P < .001 and placebo: 11.617 vs 14.027, P < .001). Intergroup comparison did not show any significant difference in IIEF scores (mean change in tadalafil vs placebo group: 3.719 vs 4.433, P ¼ .223) and FMD% (mean change tadalafil vs placebo group: 2.426 and 2.829, P ¼ .528). The adverse events were significantly more in the tadalafil group (tadalafil vs placebo 14 adverse reactions [ADR] vs 5 ADR, P < .001). Conclusion: The response of low-dose tadalafil on IIEF and FMD is largely similar to placebo; however, the utility of FMD% in young patients and placebo effect needs to be studied further. </p><p></p><p></p><p></p><p></p><p></p><p><strong>CONCLUSION</strong> </p><p>We conclude that the response of low-dose, once-daily tadalafil (10 mg per day) over a short-term period (4 weeks) on IIEF and FMD is largely similar to placebo in younger subjects without any comorbidities, except those with severe ED. However, to draw meaningful conclusions, further studies are warranted.</p></blockquote><p></p>
[QUOTE="madman, post: 134857, member: 13851"] [B][COLOR=rgb(184, 49, 47)]Objective: [/COLOR][/B]To assess whether tadalafil improves endothelial dysfunction(EnD) in a placebo-controlled randomized-control trial. [B][COLOR=rgb(184, 49, 47)]Methods:[/COLOR][/B] Erectile dysfunction and EnD were assessed by the International Index of Erectile Function (IIEF-5) and flow-mediated dilation (FMD) of the brachial artery respectively, at baseline and 4 weeks by blinded observer. Patients with FMD of < 15% were randomized in 1:1 ratio to receive either placebo or tadalafil. Both placebo and tadalafil in similar-appearing capsules but coded separately, were dispensed by a blinded co-investigator. Compliance and drug-related events were recorded. The randomization codes were then decoded and appropriate statistical tests applied. [B][COLOR=rgb(184, 49, 47)]Results: [/COLOR][/B]89 patients were randomized and 82 completed the study. Both groups were comparable. Posttreatment, there were significant improvements in IIEF-5 score (pre- vs post treatment; tadalafil: 11.432 vs 15.937, P < .001 and placebo 11.232 vs 14.935, P < .00) and FMD% pre- vs post treatment; tadalafil: 11.222 vs 13.827, P < .001 and placebo: 11.617 vs 14.027, P < .001). Intergroup comparison did not show any significant difference in IIEF scores (mean change in tadalafil vs placebo group: 3.719 vs 4.433, P ¼ .223) and FMD% (mean change tadalafil vs placebo group: 2.426 and 2.829, P ¼ .528). The adverse events were significantly more in the tadalafil group (tadalafil vs placebo 14 adverse reactions [ADR] vs 5 ADR, P < .001). Conclusion: The response of low-dose tadalafil on IIEF and FMD is largely similar to placebo; however, the utility of FMD% in young patients and placebo effect needs to be studied further. [B]CONCLUSION[/B] We conclude that the response of low-dose, once-daily tadalafil (10 mg per day) over a short-term period (4 weeks) on IIEF and FMD is largely similar to placebo in younger subjects without any comorbidities, except those with severe ED. However, to draw meaningful conclusions, further studies are warranted. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
Endothelial Dysfunction in Patients With Erectile Dysfunction: A Double-Blind, Randomized-Control Trial Using Tadalafil
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top